Bruker Corporation
General ticker "BRKR" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $6.5B (TTM average)
Bruker Corporation follows the US Stock Market performance with the rate: 6.4%.
Estimated limits based on current volatility of 2.3%: low 46.89$, high 49.12$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-09-23, amount 0.05$ (Y0.41%)
- Total employees count: 11396 (+17.4%) as of 2024
- China accounted for 14.0% of revenue in the fiscal year ended 2024-12-31
- US accounted for 27.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Geopolitical risks, Economic downturns and volatility, Cybersecurity threats, Liquidity and credit risks
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [40.47$, 66.06$]
- 2025-12-31 to 2026-12-31 estimated range: [41.00$, 66.35$]
Financial Metrics affecting the BRKR estimates:
- Negative: with PPE of 23.8 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 7.52
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 30.67 <= 41.86
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 1.92
- Positive: Inventory ratio change, % of -0.33 <= 0
- Negative: Industry earnings per price (median), % of -3.67 <= 0
- Positive: Interest expense per share per price, % of 0.56 <= 0.79
Short-term BRKR quotes
Long-term BRKR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,530.70MM | $2,964.50MM | $3,366.40MM |
| Operating Expenses | $2,098.00MM | $2,527.60MM | $3,113.30MM |
| Operating Income | $432.70MM | $436.90MM | $253.10MM |
| Non-Operating Income | $-18.80MM | $109.30MM | $-47.90MM |
| Interest Expense | $0.00MM | $16.40MM | $47.90MM |
| R&D Expense | $235.90MM | $294.80MM | $376.50MM |
| Income(Loss) | $413.90MM | $546.20MM | $205.20MM |
| Taxes | $116.40MM | $117.70MM | $91.40MM |
| Profit(Loss)* | $296.60MM | $427.20MM | $113.10MM |
| Stockholders Equity | $1,113.80MM | $1,377.20MM | $1,781.20MM |
| Inventory | $800.10MM | $968.30MM | $1,067.80MM |
| Assets | $3,611.80MM | $4,249.90MM | $5,806.70MM |
| Operating Cash Flow | $274.40MM | $350.10MM | $251.30MM |
| Capital expenditure | $129.20MM | $106.90MM | $115.30MM |
| Investing Cash Flow | $-251.60MM | $-326.00MM | $-1,757.30MM |
| Financing Cash Flow | $-415.30MM | $-193.40MM | $1,229.80MM |
| Earnings Per Share** | $2.00 | $2.92 | $0.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.